Real Life Sciences, LLC

Founded in 2015 by Nathan Artz and based in Wayne, US, Real Life Sciences provides data anonymization solutions for the life sciences sector. In January 2025, MMIS, Inc. , a portfolio company of EDG Partners, and Susquehanna Growth Equity acquired Real Life Sciences. Real Life Sciences (RLS) specializes in advanced data and document anonymization and redaction solutions, primarily through its flagship product, RLS PROTECT.

This software helps pharmaceutical sponsors and contract research organizations (CROs) comply with regulatory transparency requirements set forth by Health Canada, the European Medicines Agency (EMA), and the U. S. Food and Drug Administration (FDA). RLS PROTECT employs advanced quantitative risk modeling techniques to anonymize personal and confidential information, enabling clients to securely share clinical trial data with health authorities and partners.

The company serves a global client base, including leading life sciences firms, regulatory bodies, and research organizations across North America, Europe, and Asia, addressing their needs for compliance in clinical data disclosures and secondary research initiatives. Real Life Sciences generates revenue through its software-as-a-service (SaaS) model, offering subscription-based access to its RLS PROTECT platform and associated anonymization services. The firm's revenue structure is primarily B2B, focusing on long-term partnerships with pharmaceutical manufacturers and CROs who require ongoing support for regulatory submissions and data sharing.